Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
WYE-354
Cat. No.:
OB0225LY-0388
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
WYE-354 is a small molecule inhibitor of the selective interferon gamma (IFN-γ) signaling pathway.
Synonym:
1062169-56-5; Methyl 4-[6-[4-(methoxycarbonylamino)phenyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate; Methyl 4-(6-(4-((methoxycarbonyl)amino)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
CAS No.:
1062169-56-5
Compound CID:
44219749
Formula:
C24H29N7O5
Formula Weight:
495.53
Specification
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
WYE-354 can be used in immunological studies or play an important role in models of chronic inflammation and autoimmune diseases.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR; PI3Kα; PI3Kγ
Pathways:
Apoptosis; Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-6
Plate Location:
a3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
92 mg/mL; 185.7 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
1.886
HBA_Count:
8
HBD_Count:
1
Rotatable Bond:
6
